A Phase Ia/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients With Heart Failure (HFrEF and HF With EF ≥ 41%)
Latest Information Update: 21 Oct 2022
Price :
$35 *
At a glance
- Drugs AZD 3427 (Primary) ; AZD 3427 (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 19 Oct 2022 Status changed from active, no longer recruiting to completed.
- 19 Aug 2022 Planned End Date changed from 20 Sep 2022 to 14 Sep 2022.
- 19 Aug 2022 Planned primary completion date changed from 20 Sep 2022 to 14 Sep 2022.